S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$199.60
$199.98
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
1.86 million shs
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$162.70

Prometheus Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
18.6% Downside
$162.70 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.84) to ($4.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.71 out of 5 stars

Medical Sector

960th out of 962 stocks

Biotechnology Industry

13th out of 14 stocks


RXDX stock logo

About Prometheus Biosciences (NASDAQ:RXDX) Stock

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.


RXDX Stock News Headlines

Prometheus Biosciences (NASDAQ: RXDX)
Experts: "NVIDIA Bubble" Could Affect Entire Market
Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.
Experts: "NVIDIA Bubble" Could Affect Entire Market
Several major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.
RBC Capital downgrades Prometheus Biosciences (RXDX) to a Hold
How to Tell Biotech’s Likely Winners From Losers
Healthcare Is Back. But Is It Here to Stay?
See More Headlines
Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Company Calendar

Last Earnings
5/09/2023
Today
9/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
97
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$162.70
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$111.00
Forecasted Upside/Downside
-18.6%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$-141,750,000.00
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%

Debt

Sales & Book Value

Annual Sales
$6.81 million
Book Value
$16.12 per share

Miscellaneous

Free Float
46,187,000
Market Cap
$9.56 billion
Optionable
Not Optionable
Beta
-0.49

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Mark C. McKenna (Age 43)
    Pres, CEO & Chairman
    Comp: $1.33M
  • Dr. Keith W. Marshall M.B.A. (Age 55)
    MBA, Ph.D., Chief Financial Officer
    Comp: $829.45k
  • Mr. Mark Stenhouse (Age 56)
    Chief Operating Officer
    Comp: $807.4k
  • Dr. Olivier Laurent Ph.D. (Age 51)
    Chief Scientific Officer & Head of R&D
  • Ms. Noel Kurdi
    VP of Investor Relations & Communications
  • Mr. Timothy K. Andrews Esq. (Age 44)
    Gen. Counsel & Sec.
  • Ms. Nori Ebersole (Age 59)
    Chief People Officer
  • Dr. Allison Luo M.D. (Age 50)
    Chief Medical Officer
  • Dr. Thierry Dervieux DABCC (Age 55)
    Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director
  • Mr. Chris Doughty
    Chief Bus. Officer













RXDX Stock - Frequently Asked Questions

Should I buy or sell Prometheus Biosciences stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares.
View RXDX analyst ratings
or view top-rated stocks.

What is Prometheus Biosciences' stock price forecast for 2023?

10 brokers have issued 1 year target prices for Prometheus Biosciences' shares. Their RXDX share price forecasts range from $111.00 to $200.00. On average, they predict the company's stock price to reach $162.70 in the next twelve months. This suggests that the stock has a possible downside of 18.6%.
View analysts price targets for RXDX
or view top-rated stocks among Wall Street analysts.

How were Prometheus Biosciences' earnings last quarter?

Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.06. The biopharmaceutical company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative net margin of 3,768.76% and a negative trailing twelve-month return on equity of 33.50%. The company's quarterly revenue was down 71.8% on a year-over-year basis.

What ETF holds Prometheus Biosciences' stock ?

Vanguard Russell 2000 Growth ETF holds 27,868 shares of RXDX stock, representing 0.58% of its portfolio.

What other stocks do shareholders of Prometheus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD).

When did Prometheus Biosciences IPO?

(RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Prometheus Biosciences' stock symbol?

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Who are Prometheus Biosciences' major shareholders?

Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Walleye Trading LLC (0.00%), Citadel Advisors LLC (0.00%), HAP Trading LLC (0.00%), Citigroup Inc. (0.00%), Belvedere Trading LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse, Perceptive Advisors Llc and Sinai Intellectual Prop Cedars.
View institutional ownership trends
.

What is Prometheus Biosciences' stock price today?

One share of RXDX stock can currently be purchased for approximately $199.92.

How much money does Prometheus Biosciences make?

Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $9.56 billion and generates $6.81 million in revenue each year. The biopharmaceutical company earns $-141,750,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

Does Prometheus Biosciences have any subsidiaries?
The following companies are subsidiares of Prometheus Biosciences: Prometheus Laboratories Inc..
Read More
How can I contact Prometheus Biosciences?

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com.

This page (NASDAQ:RXDX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -